Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

@article{Weber2003PositronET,
  title={Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.},
  author={Wolfgang Weber and Volker Petersen and Burkhard Schmidt and Leishia Tyndale-Hines and Thomas Link and Christian Peschel and Markus Schwaiger},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 14},
  pages={2651-7}
}
PURPOSE To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with stage IIIB or IV NSCLC scheduled to undergo platinum-based chemotherapy were eligible for this study. Patients were studied by FDG-PET before and after the first cycle of therapy. Based on previous studies, a reduction of tumor FDG… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 158 extracted citations

Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2017
View 2 Excerpts
Highly Influenced

Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2009
View 3 Excerpts
Highly Influenced

Feasibility of state of the art PET/CT systems performance harmonisation

European Journal of Nuclear Medicine and Molecular Imaging • 2018

Similar Papers

Loading similar papers…